These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Peters S; Scherpereel A; Cornelissen R; Oulkhouir Y; Greillier L; Kaplan MA; Talbot T; Monnet I; Hiret S; Baas P; Nowak AK; Fujimoto N; Tsao AS; Mansfield AS; Popat S; Zhang X; Hu N; Balli D; Spires T; Zalcman G Ann Oncol; 2022 May; 33(5):488-499. PubMed ID: 35124183 [TBL] [Abstract][Full Text] [Related]
3. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. Scherpereel A; Antonia S; Bautista Y; Grossi F; Kowalski D; Zalcman G; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Sun X; Lawrance R; Zhang X; Daumont MJ; Bennett B; McKenna M; Baas P Lung Cancer; 2022 May; 167():8-16. PubMed ID: 35367910 [TBL] [Abstract][Full Text] [Related]
4. Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies. Hu ZI; Ghafoor A; Sengupta M; Hassan R Cancer; 2021 Apr; 127(7):1010-1020. PubMed ID: 33620732 [TBL] [Abstract][Full Text] [Related]
5. Nivolumab plus ipilimumab in malignant pleural mesothelioma. Travert C; Tomasini P; Greillier L Expert Rev Anticancer Ther; 2022 Aug; 22(8):815-822. PubMed ID: 35835722 [TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma. Metro G; Signorelli D; Pizzutilo EG; Giannetta L; Cerea G; Garaffa M; Friedlaender A; Addeo A; Mandarano M; Bellezza G; Roila F Hum Vaccin Immunother; 2021 Sep; 17(9):2972-2980. PubMed ID: 34003722 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials. Mankor JM; Disselhorst MJ; Poncin M; Baas P; Aerts JGJV; Vroman H EBioMedicine; 2020 Dec; 62():103040. PubMed ID: 33166791 [TBL] [Abstract][Full Text] [Related]
8. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma. Haakensen VD; Nowak AK; Ellingsen EB; Farooqi SJ; Bjaanæs MM; Horndalsveen H; Mcculloch T; Grundberg O; Cedres SM; Helland Å J Transl Med; 2021 May; 19(1):232. PubMed ID: 34059094 [TBL] [Abstract][Full Text] [Related]
14. Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review). Rijavec E; Biello F; Barletta G; Dellepiane C; Genova C Mol Clin Oncol; 2022 Apr; 16(4):89. PubMed ID: 35251640 [TBL] [Abstract][Full Text] [Related]
15. [Anti-tumor immunotherapy in malignant pleural mesothelioma]. Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822 [TBL] [Abstract][Full Text] [Related]
16. [Advances in Immunotherapy for Malignant Pleural Mesothelioma]. Chi Y; Liu Y; Zhao J Zhongguo Fei Ai Za Zhi; 2022 Apr; 25(4):259-265. PubMed ID: 35477190 [TBL] [Abstract][Full Text] [Related]
17. Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma. Gray SG BMC Pulm Med; 2021 May; 21(1):148. PubMed ID: 33952230 [TBL] [Abstract][Full Text] [Related]
18. Advances in Immunotherapy of Malignant Pleural Mesothelioma. Liao D; Yu Y; Mei Q; Wang Z; Li X; Jia Y; Kong F Onco Targets Ther; 2021; 14():4477-4484. PubMed ID: 34429612 [TBL] [Abstract][Full Text] [Related]
20. Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes. Jones RG; Karthik F; Dugar A; Kanagarajan K; Desai K; Bhandari M Am J Case Rep; 2018 Jul; 19():783-789. PubMed ID: 29970876 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]